The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma

Eugene P. Toy, Joseph T. Chambers, Barry M. Kacinski, Maryann B. Flick, Setsuko K Chambers

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Objective. We have previously shown that the macrophage colony-stimulating factor receptor (CSF-1R) and its ligand, CSF-1, together predict poor prognosis in epithelial ovarian carcinoma. The activated or phosphorylated form of CSF-1R (CSF-1Rphos) has been associated with enhanced invasive and metastatic potential. Our goal is to correlate CSF-1Rphos with known prognostic factors and to determine its role in predicting outcome in advanced ovarian cancer. Methods. One hundred forty-two primary and forty-seven metastatic epithelial ovarian tumors from 98 patients were immunohistochemically stained using antibodies PY809 and PY723 against their respective tyrosine residues associated with local invasiveness and metastasis. X 2 analysis was used to correlate CSF-1Rphos staining and previously studied prognosticators within each group. Kaplan-Meier curves of survival were compared using the log-rank test with significance of P < 0.05. Results. Forty-seven and nine-tenths percent (68/142) of primary tumors and forty-eight and nine-tenths percent (23/47) of metastatic tumors stained positive for PY809 and PY723, respectively. The PY809+ group was strongly associated with CSF-1R (P = 0.015) as was the PY723+ group (P = 0.025) in its respective subset. CSF-1Rphos by itself was not a predictor of survival or disease-free interval (DFI) in either the primary or metastatic group. However, when combined with CSF-1R in the metastatic group, the two together predicted worse survival (P = 0.007) and decreased DFI (P = 0.011). Conclusions. Phosphorylated tyrosine kinase receptors are detectable in a significant number of ovarian tumors. Staining strongly correlates with CSF-1R. PY723+ metastases coexpressing CSF-1R portend a highly significant decrease in survival and increased risk of recurrence which may serve to identify high-risk ovarian cancer patients.

Original languageEnglish (US)
Pages (from-to)194-200
Number of pages7
JournalGynecologic Oncology
Volume80
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Macrophage Colony-Stimulating Factor Receptors
Macrophage Colony-Stimulating Factor
Carcinoma
Ovarian Neoplasms
Neoplasms
Staining and Labeling
Neoplasm Metastasis
Survival
Kaplan-Meier Estimate
Receptor Protein-Tyrosine Kinases
Disease-Free Survival
Tyrosine
Ligands
Recurrence
Antibodies

Keywords

  • Macrophage colony-stimulating factor
  • Ovarian carcinoma
  • Tumor marker

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. / Toy, Eugene P.; Chambers, Joseph T.; Kacinski, Barry M.; Flick, Maryann B.; Chambers, Setsuko K.

In: Gynecologic Oncology, Vol. 80, No. 2, 2001, p. 194-200.

Research output: Contribution to journalArticle

Toy, Eugene P. ; Chambers, Joseph T. ; Kacinski, Barry M. ; Flick, Maryann B. ; Chambers, Setsuko K. / The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. In: Gynecologic Oncology. 2001 ; Vol. 80, No. 2. pp. 194-200.
@article{387e2691045444ad96eb0e2144ac3bb0,
title = "The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma",
abstract = "Objective. We have previously shown that the macrophage colony-stimulating factor receptor (CSF-1R) and its ligand, CSF-1, together predict poor prognosis in epithelial ovarian carcinoma. The activated or phosphorylated form of CSF-1R (CSF-1Rphos) has been associated with enhanced invasive and metastatic potential. Our goal is to correlate CSF-1Rphos with known prognostic factors and to determine its role in predicting outcome in advanced ovarian cancer. Methods. One hundred forty-two primary and forty-seven metastatic epithelial ovarian tumors from 98 patients were immunohistochemically stained using antibodies PY809 and PY723 against their respective tyrosine residues associated with local invasiveness and metastasis. X 2 analysis was used to correlate CSF-1Rphos staining and previously studied prognosticators within each group. Kaplan-Meier curves of survival were compared using the log-rank test with significance of P < 0.05. Results. Forty-seven and nine-tenths percent (68/142) of primary tumors and forty-eight and nine-tenths percent (23/47) of metastatic tumors stained positive for PY809 and PY723, respectively. The PY809+ group was strongly associated with CSF-1R (P = 0.015) as was the PY723+ group (P = 0.025) in its respective subset. CSF-1Rphos by itself was not a predictor of survival or disease-free interval (DFI) in either the primary or metastatic group. However, when combined with CSF-1R in the metastatic group, the two together predicted worse survival (P = 0.007) and decreased DFI (P = 0.011). Conclusions. Phosphorylated tyrosine kinase receptors are detectable in a significant number of ovarian tumors. Staining strongly correlates with CSF-1R. PY723+ metastases coexpressing CSF-1R portend a highly significant decrease in survival and increased risk of recurrence which may serve to identify high-risk ovarian cancer patients.",
keywords = "Macrophage colony-stimulating factor, Ovarian carcinoma, Tumor marker",
author = "Toy, {Eugene P.} and Chambers, {Joseph T.} and Kacinski, {Barry M.} and Flick, {Maryann B.} and Chambers, {Setsuko K}",
year = "2001",
doi = "10.1006/gyno.2000.6070",
language = "English (US)",
volume = "80",
pages = "194--200",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma

AU - Toy, Eugene P.

AU - Chambers, Joseph T.

AU - Kacinski, Barry M.

AU - Flick, Maryann B.

AU - Chambers, Setsuko K

PY - 2001

Y1 - 2001

N2 - Objective. We have previously shown that the macrophage colony-stimulating factor receptor (CSF-1R) and its ligand, CSF-1, together predict poor prognosis in epithelial ovarian carcinoma. The activated or phosphorylated form of CSF-1R (CSF-1Rphos) has been associated with enhanced invasive and metastatic potential. Our goal is to correlate CSF-1Rphos with known prognostic factors and to determine its role in predicting outcome in advanced ovarian cancer. Methods. One hundred forty-two primary and forty-seven metastatic epithelial ovarian tumors from 98 patients were immunohistochemically stained using antibodies PY809 and PY723 against their respective tyrosine residues associated with local invasiveness and metastasis. X 2 analysis was used to correlate CSF-1Rphos staining and previously studied prognosticators within each group. Kaplan-Meier curves of survival were compared using the log-rank test with significance of P < 0.05. Results. Forty-seven and nine-tenths percent (68/142) of primary tumors and forty-eight and nine-tenths percent (23/47) of metastatic tumors stained positive for PY809 and PY723, respectively. The PY809+ group was strongly associated with CSF-1R (P = 0.015) as was the PY723+ group (P = 0.025) in its respective subset. CSF-1Rphos by itself was not a predictor of survival or disease-free interval (DFI) in either the primary or metastatic group. However, when combined with CSF-1R in the metastatic group, the two together predicted worse survival (P = 0.007) and decreased DFI (P = 0.011). Conclusions. Phosphorylated tyrosine kinase receptors are detectable in a significant number of ovarian tumors. Staining strongly correlates with CSF-1R. PY723+ metastases coexpressing CSF-1R portend a highly significant decrease in survival and increased risk of recurrence which may serve to identify high-risk ovarian cancer patients.

AB - Objective. We have previously shown that the macrophage colony-stimulating factor receptor (CSF-1R) and its ligand, CSF-1, together predict poor prognosis in epithelial ovarian carcinoma. The activated or phosphorylated form of CSF-1R (CSF-1Rphos) has been associated with enhanced invasive and metastatic potential. Our goal is to correlate CSF-1Rphos with known prognostic factors and to determine its role in predicting outcome in advanced ovarian cancer. Methods. One hundred forty-two primary and forty-seven metastatic epithelial ovarian tumors from 98 patients were immunohistochemically stained using antibodies PY809 and PY723 against their respective tyrosine residues associated with local invasiveness and metastasis. X 2 analysis was used to correlate CSF-1Rphos staining and previously studied prognosticators within each group. Kaplan-Meier curves of survival were compared using the log-rank test with significance of P < 0.05. Results. Forty-seven and nine-tenths percent (68/142) of primary tumors and forty-eight and nine-tenths percent (23/47) of metastatic tumors stained positive for PY809 and PY723, respectively. The PY809+ group was strongly associated with CSF-1R (P = 0.015) as was the PY723+ group (P = 0.025) in its respective subset. CSF-1Rphos by itself was not a predictor of survival or disease-free interval (DFI) in either the primary or metastatic group. However, when combined with CSF-1R in the metastatic group, the two together predicted worse survival (P = 0.007) and decreased DFI (P = 0.011). Conclusions. Phosphorylated tyrosine kinase receptors are detectable in a significant number of ovarian tumors. Staining strongly correlates with CSF-1R. PY723+ metastases coexpressing CSF-1R portend a highly significant decrease in survival and increased risk of recurrence which may serve to identify high-risk ovarian cancer patients.

KW - Macrophage colony-stimulating factor

KW - Ovarian carcinoma

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=0035135492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035135492&partnerID=8YFLogxK

U2 - 10.1006/gyno.2000.6070

DO - 10.1006/gyno.2000.6070

M3 - Article

C2 - 11161859

AN - SCOPUS:0035135492

VL - 80

SP - 194

EP - 200

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -